An artificial pancreas usually refers to an automated insulin-delivery system: a glucose sensor, control software and a pump working together. The insulin still comes from the supplied medicine. Islet transplantation instead introduces living insulin-producing cells. These approaches can both address glucose control without being versions of the same procedure. 1 2
The comparison is not “old treatment versus future cure.” It is a comparison of different sources of insulin, different burdens and different claims.
Start with what is being replaced
NIDDK describes an artificial-pancreas system as a continuous glucose monitor communicating with an algorithm and insulin pump. Hybrid systems still need information such as carbohydrate intake. Automation does not mean the user never maintains equipment or responds to a problem. 1
Donor islets are transplanted into a recipient, typically through the liver's portal vein. They can produce insulin, but immune-suppressing medication and clinical follow-up remain important parts of donor-islet treatment. That risk-and-maintenance profile is not the same as wearing a pump. 2
| Question | Automated delivery | Islet transplantation |
|---|---|---|
| Where does insulin come from? | Medicine supplied to the system | Living transplanted cells, with additional insulin sometimes still required |
| What is being automated or restored? | The adjustment and delivery of insulin | A biological source of insulin production |
| What ongoing burden matters? | Device wear, supplies, system maintenance and appropriate user input | Transplant follow-up, graft durability and immune-related treatment |
| What would be the wrong shortcut? | “No more need for insulin” | “No more need for medical treatment” |
The table summarizes the two mechanisms and their different operating burdens; it does not rank individual products or recommend either approach. 1 2
Why insulin independence is not a universal comparison score
A pump cannot win an “insulin independence” contest: its purpose is to deliver insulin. That does not make a measured improvement in glucose control irrelevant. Equally, an insulin-independent period after cell therapy does not establish how long it will last or what other treatment was necessary.
Our insulin-independence explainer distinguishes the endpoint from a universal cure. When comparing reports, record the job the treatment was intended to do before comparing numbers.
A meaningful comparison would hold the population, follow-up and outcome definition sufficiently close to answer a common question. A device study measuring time in glucose range and a small transplant study counting insulin-independent participants do not automatically supply that common denominator. This is an interpretation limit, not evidence that one study is worthless.
Donor islets and stem-cell-derived islets also differ
“Cell therapy” does not identify a single product. The edition's Lantidra report concerns donor-derived islets; zimislecel reporting concerns stem-cell-derived islets. Their sources, development records and evidence must remain attached to the correct program.
NIDDK describes the US donor-islet indication as a selected adult population experiencing repeated severe hypoglycemia despite intensive diabetes management and education. It is not an alternative offered on equal terms to every pump user. 2
That is why this comparison does not tell someone to replace a functioning diabetes regimen with an experimental intervention. A research article cannot make a personal treatment decision.
Compare cost categories before comparing prices
For a delivery system, the relevant price question includes the compatible components, recurring supplies, prescribed insulin and actual coverage. For a transplant strategy, it includes the cell product or procedure, associated hospital care, monitoring and continuing medicines. A single promotional product price is not a completed comparison of those costs. 1 2
No current supplier quotes or individual insurance decisions were obtained for this article. We therefore do not publish an invented “cheapest option,” lifetime savings estimate or universal treatment price. A cost comparison without the same country, coverage assumptions, time period and included services would create more apparent precision than useful information.
A practical way to read the next headline
Translate it into a sentence with four fields: the intervention, the population, the outcome and the time measured. Then add what participants still needed to do or take. That prevents “automated,” “restored” and “independent” from being used as synonyms.
For approaches intended to preserve remaining insulin production rather than supply insulin or new cells, see Tzield's two 2026 indications. These are three distinct strategies—not three positions on one guaranteed road to a cure.